In 2021, FDA approved Enhertu (conjugate fam-trastuzumab deruxtecan) as the treatment for advanced HER2-positive gastric or GE junction adenocarcinoma in patients with a history of trastuzumab-containing chemotherapy.

👉🏻 𝐀𝐜𝐜𝐞𝐬𝐬 𝐅𝐮𝐥𝐥 𝐒𝐮𝐦𝐦𝐚𝐫𝐲: https://www.marknteladvisors.c....om/research-library/

#gastroesophageal_cancer_market #gastroesophageal #cancer #chemotherapy #alcohol #obesity #gastric #ulcerativecolitis #healthcare #marketresearch #marknteladvisors

image